Novo Nordisk, the manufacturer of the FDA-approved commercial product, uses yeast-based recombinant RNA methods to make semaglutide
The combination of targeting both GLP-1 and GIP receptors, as seen with tirzepatide, is thought to provide synergistic effects on glucose control and weight management
However, a total variability in semaglutide exposure of 6585% was observed, suggesting that some between-subject variability occurs in the absorption of oral semaglutide
Eat smaller, balanced meals to reduce nausea and digestive discomfort
Real-world retrospective study into the effects of oral semaglutide (as a switchover or add-on therapy) in type 2 diabetes
Continue With Professional Guidance Its hard to lose weight by yourself